BULN
MCID: BLM002
MIFTS: 56

Bulimia Nervosa (BULN)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Bulimia Nervosa

MalaCards integrated aliases for Bulimia Nervosa:

Name: Bulimia Nervosa 57 12 73 54 44 15 17 70 32
Bulimia Nervosa, Susceptibility to 57 13
Bulimia 44 70
Bulimia Nervosa, Susceptibility to, Type 2 39
Susceptibility to Bulimia Nervosa 29
Binge Eating Disorder 70
Hyperorexia Nervosa 12
Bulimia Nervosa 2 72
Buln2 72
Buln 57
Bn 57

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
multifactorial


HPO:

31
bulimia nervosa:
Inheritance multifactorial inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:12129
OMIM® 57 607499
NCIt 50 C97162
SNOMED-CT 67 78004001
ICD10 32 F50.2
UMLS 70 C0006370 C0596170 C2267227

Summaries for Bulimia Nervosa

OMIM® : 57 Bulimia nervosa (BN) is a psychiatric disorder characterized by episodes of binge-eating (eating an unusually large amount of food in a discrete period of time and feeling out of control), compensatory behavior (e.g., self-induced vomiting or laxative abuse), and over-concern with weight and shape. Eating disorders such as bulimia nervosa are complex disorders that can be influenced by many genes. (607499) (Updated 20-May-2021)

MalaCards based summary : Bulimia Nervosa, also known as bulimia nervosa, susceptibility to, is related to amenorrhea and eating disorder, and has symptoms including salt craving, decrease in appetite and symptoms. An important gene associated with Bulimia Nervosa is BULN (Bulimia Nervosa, Susceptibility To), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Sibutramine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and bone, and related phenotypes are bulimia and behavior/neurological

Disease Ontology : 12 An eating disorder characterized by the restraining of food intake for a period of time followed by an over intake or binging period that results in feelings of guilt and low self-esteem.

UniProtKB/Swiss-Prot : 72 Bulimia nervosa 2: A psychiatric disorder characterized by eating an unusually large amount of food in a short period of time, followed by inappropriate acts (purging) to avert weight gain. Compensatory behavior includes self-induced vomiting, laxative abuse, and excessive exercise.

Wikipedia : 73 Bulimia nervosa, also known as simply bulimia, is an eating disorder characterized by binge eating... more...

Related Diseases for Bulimia Nervosa

Diseases related to Bulimia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 amenorrhea 30.7 LEP INS GHRL
2 eating disorder 30.5 SLC6A4 PYY NPY MC4R LEPQTL1 LEP
3 gastroesophageal reflux 30.4 PYY NPY HTR2A GHRL CCK
4 alexithymia 30.4 SLC6A4 OXT DRD2 COMT
5 obsessive-compulsive personality disorder 30.2 SLC6A4 HTR2A COMT
6 agoraphobia 30.1 SLC6A4 MAOA HTR2A COMT
7 body dysmorphic disorder 30.1 SLC6A4 OXT MAOA HTR2A
8 acute stress disorder 30.1 SLC6A4 OXT BDNF
9 anovulation 30.1 LEP INS GHRL
10 headache 30.0 SLC6A4 COMT CCK
11 depression 30.0 SLC6A4 MAOA HTR3A HTR2C HTR2A BDNF
12 somatization disorder 30.0 SLC6A4 OXT COMT
13 hyperthyroidism 30.0 LEP INS GHRL
14 post-traumatic stress disorder 30.0 SLC6A4 MAOA HTR2A DRD2 COMT BDNF
15 celiac disease 1 30.0 PYY INS GHRL CCK
16 conduct disorder 30.0 SLC6A4 MAOA DRD4 DRD2 COMT
17 kleptomania 29.9 SLC6A4 MAOA DRD2 COMT
18 postpartum depression 29.9 SLC6A4 OXT MAOA COMT BDNF
19 hyperglycemia 29.9 PYY LEP INS GHRL CCK
20 atypical depressive disorder 29.9 SLC6A4 MAOA LEP HTR2A BDNF
21 nutritional deficiency disease 29.9 NPY LEPQTL1 LEP GHRL CCK BDNF
22 drug dependence 29.8 SLC6A4 HTR3A DRD2 BDNF
23 narcissistic personality disorder 29.8 OXT MAOA
24 conversion disorder 29.7 HTR2A COMT BDNF
25 substance dependence 29.7 SLC6A4 MAOA HTR1B DRD4 DRD2 COMT
26 diarrhea 29.7 SLC6A4 PYY LEP HTR3A CCK
27 pica disease 29.6 LEP INS
28 melancholia 29.6 SLC6A4 MAOA HTR2A BDNF
29 neurotic disorder 29.6 SLC6A4 OXT MAOA INS HTR2A COMT
30 congenital generalized lipodystrophy 29.6 LEPQTL1 LEP INS
31 separation anxiety disorder 29.6 SLC6A4 OXT MAOA DRD4 COMT
32 pathological gambling 29.6 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
33 cholelithiasis 29.5 LEP INS CCK
34 delusional disorder 29.4 HTR2C HTR2A DRD4 DRD2
35 autonomic neuropathy 29.4 NPY INS CCK
36 personality disorder 29.4 SLC6A4 MAOA HTR3A HTR2C HTR2A HTR1B
37 sexual disorder 29.4 SLC6A4 OXT INS HTR2C HTR2A BDNF
38 phobia, specific 29.3 SLC6A4 OXT MAOA HTR2A COMT BDNF
39 borderline personality disorder 29.3 SLC6A4 MAOA HTR3A HTR2C HTR2A HTR1B
40 constipation 29.3 SLC6A4 PYY NPY INS HTR3A GHRL
41 alcohol use disorder 29.3 SLC6A4 HTR3A HTR2C HTR2A HTR1B DRD2
42 bipolar i disorder 29.3 SLC6A4 HTR2C HTR2A DRD2 COMT BDNF
43 substance abuse 29.2 SLC6A4 NPY MAOA INS HTR2A HTR1B
44 anorexia nervosa 29.2 SLC6A4 PYY OXT NPY MC4R MAOA
45 generalized anxiety disorder 29.1 SLC6A4 NPY MAOA HTR3A HTR2A DRD2
46 tobacco addiction 29.1 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
47 antisocial personality disorder 29.0 SLC6A4 OXT MAOA HTR2A HTR1B DRD4
48 irritable bowel syndrome 29.0 SLC6A4 PYY HTR3A HTR2A GHRL COMT
49 dysthymic disorder 29.0 SLC6A4 MAOA INS HTR2C HTR2A DRD4
50 leptin deficiency or dysfunction 29.0 PYY OXT NPY MC4R LEP INS

Graphical network of the top 20 diseases related to Bulimia Nervosa:



Diseases related to Bulimia Nervosa

Symptoms & Phenotypes for Bulimia Nervosa

Human phenotypes related to Bulimia Nervosa:

31
# Description HPO Frequency HPO Source Accession
1 bulimia 31 HP:0100739

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Neurologic Behavioral Psychiatric Manifestations:
recurrent episodes of binge eating
recurrent inappropriate conpensatory behavior to prevent weight gain, including self-induced vomiting, laxative or diuretic abuse, fasting, excessive exercise
overconcern with weight and body shape
feelings of guilt associated with episodes

Clinical features from OMIM®:

607499 (Updated 20-May-2021)

UMLS symptoms related to Bulimia Nervosa:


salt craving; decrease in appetite; symptoms

MGI Mouse Phenotypes related to Bulimia Nervosa:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 BDNF CCK COMT DRD2 DRD4 GHRL
2 homeostasis/metabolism MP:0005376 10.16 BDNF CCK COMT DRD2 DRD4 GHRL
3 adipose tissue MP:0005375 10.13 DRD2 GHRL HTR1B HTR2C INS LEP
4 endocrine/exocrine gland MP:0005379 10.1 BDNF CCK COMT DRD2 GHRL HTR1B
5 digestive/alimentary MP:0005381 10.02 BDNF DRD2 GHRL HTR2A INS LEP
6 nervous system MP:0003631 9.83 BDNF CCK COMT DRD2 DRD4 HTR2C
7 muscle MP:0005369 9.76 DRD2 HTR1B HTR2A HTR2C HTR3A INS
8 renal/urinary system MP:0005367 9.23 CCK COMT DRD2 HTR3A INS LEP

Drugs & Therapeutics for Bulimia Nervosa

Drugs for Bulimia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
2
Memantine Approved, Investigational Phase 4 19982-08-2 4054
3
Liraglutide Approved Phase 4 204656-20-2 44147092
4
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
5
Norepinephrine Approved Phase 4 51-41-2 439260
6 Anti-Obesity Agents Phase 4
7 Appetite Depressants Phase 4
8 Hormone Antagonists Phase 4
9 Antiparkinson Agents Phase 4
10 Atomoxetine Hydrochloride Phase 4
11 Excitatory Amino Acid Antagonists Phase 4
12 Incretins Phase 4
13 Analgesics Phase 4
14 Duloxetine Hydrochloride Phase 4
15 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
16
Naloxone Approved, Vet_approved Phase 2, Phase 3 465-65-6 5284596
17
Acamprosate Approved, Investigational Phase 2, Phase 3 77337-76-9 71158
18
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
19
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 5360545
20
Lamotrigine Approved, Investigational Phase 3 84057-84-1 3878
21
Zonisamide Approved, Investigational Phase 3 68291-97-4 5734
22
tannic acid Approved Phase 2, Phase 3 1401-55-4
23
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
24
Ethanol Approved Phase 2, Phase 3 64-17-5 702
25
Naltrexone Approved, Investigational, Vet_approved Phase 2, Phase 3 16590-41-3 5360515
26
Bupropion Approved Phase 2, Phase 3 34911-55-2, 34841-39-9 444
27
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
28
Phenol Approved, Experimental Phase 3 108-95-2 996
29
Glucagon Approved Phase 3 16941-32-5
30 Anesthetics Phase 2, Phase 3
31 Diuretics, Potassium Sparing Phase 3
32 Anesthetics, General Phase 2, Phase 3
33 Anesthetics, Intravenous Phase 2, Phase 3
34 Sodium Channel Blockers Phase 3
35 calcium channel blockers Phase 3
36 Antipsychotic Agents Phase 3
37 Calcium, Dietary Phase 3
38 Narcotics Phase 2, Phase 3
39 Narcotic Antagonists Phase 2, Phase 3
40 Bupropion hydrochloride, naltrexone hydrochoride drug combination Phase 2, Phase 3
41 Anti-Infective Agents Phase 2, Phase 3
42 Respiratory System Agents Phase 2, Phase 3
43 Antidotes Phase 2, Phase 3
44 Expectorants Phase 2, Phase 3
45 Antiviral Agents Phase 2, Phase 3
46 N-monoacetylcystine Phase 2, Phase 3
47 Glucagon-Like Peptide 1 Phase 3
48
Calcium Nutraceutical Phase 3 7440-70-2 271
49
Phentermine Approved, Illicit Phase 2 122-09-8 4771
50
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients Completed NCT00327834 Phase 4 atomoxetine
2 An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity Completed NCT00330655 Phase 4 memantine
3 A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder. Completed NCT00607789 Phase 4 Duloxetine;Placebo
4 Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
5 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
6 The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects Completed NCT01739049 Phase 4 Liraglutide
7 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF - a Multicenter Study Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
8 Solriamfetol in Binge Eating Disorder Not yet recruiting NCT04602936 Phase 4 Solriamfetol;Placebo
9 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
10 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
11 Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial Unknown status NCT01693237 Phase 2, Phase 3
12 Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
13 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
14 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
15 The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
16 The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
17 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Armodafinil;Matching placebo
18 Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder Completed NCT03717493 Phase 2, Phase 3
19 Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
20 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
21 A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
22 An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder Completed NCT02684279 Phase 3 Dasotraline
23 A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
24 A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
25 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
26 Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder Completed NCT00414167 Phase 2, Phase 3 bupropion
27 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients Completed NCT00277641 Phase 3 Lamotrigine;placebo
28 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients Completed NCT00221442 Phase 3 Zonegran;sugar pill
29 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder Completed NCT03107026 Phase 3 dasotraline 4mg;dasotraline 6mg;Placebo
30 Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder Completed NCT00307619 Phase 3 topiramate
31 A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
32 Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder Recruiting NCT03539900 Phase 2, Phase 3 Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
33 Cognitive-Behavioral and Pharmacologic Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03946111 Phase 2, Phase 3 Naltrexone and Bupropion
34 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03926052 Phase 3 Lisdexamfetamine Dimesylate;Placebo
35 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03924193 Phase 3 Lisdexamfetamine Dimesylate
36 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity Recruiting NCT03045341 Phase 2, Phase 3 NB medication (Naltrexone Bupropion combination)
37 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity Enrolling by invitation NCT03063606 Phase 2, Phase 3 NB Medication (on-going from acute treatment)
38 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity Enrolling by invitation NCT03047005 Phase 2, Phase 3 NB medication (Naltrexone Bupropion combination)
39 N-acetylcysteine in Bulimia Nervosa Terminated NCT01131572 Phase 2, Phase 3 N-acetylcysteine NAC
40 Liraglutide 3.0mg/d for the Treatment of Binge Eating Disorder Terminated NCT03279731 Phase 3 Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml;Placebo
41 N-acetylcysteine in the Treatment of Bulimia Nervosa Terminated NCT01033149 Phase 3 N-acetylcysteine
42 An Exploration of the Effects of the Dopamine Agonist Pramipexole on Binge Antecedants, Binge Frequency, and Weight in Binge Eating Disorder Withdrawn NCT01106053 Phase 3 Pramipexole
43 Effect of Lisdexamfetamine on Prefrontal Brain Dysfunction in Binge Eating Disorder Unknown status NCT02659488 Phase 2 Lisdexamfetamine
44 Effects of Erythromycin on Binge Eating and GI Function in Bulimia Nervosa Completed NCT00304187 Phase 2 Erythromycin;Placebo
45 A Randomized Comparison of Osmotic Release Oral System Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Obese Patients With Binge Eating Disorder Completed NCT01921582 Phase 2 Methylphenidate
46 Open-label Phentermine/Topiramate Extended Release (PHEN/TPM ER; Qsymia®) in Ten Subjects With Overweight or Obesity and DSM-V Binge Eating Disorder (BED) Completed NCT02659475 Phase 2 PHEN/TPM ER (Qsymia®)
47 A Double-Blind, Placebo-Controlled Study of Vortioxetine in the Treatment of Binge Eating Disorder Completed NCT02528409 Phase 2 Vortioxetine;Placebo
48 Chromium Picolinate in Binge Eating Disorder: A Feasibility Study Completed NCT00904306 Phase 1, Phase 2
49 A Randomized Comparison of Group-Behavioral Therapy and Group Interpersonal Psychotherapy for the Treatment of Overweight Individuals With Binge-Eating Disorder Completed NCT01208272 Phase 1, Phase 2
50 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Pilot Study of the Safety and Efficacy of RDC-0313 in Adults With Binge Eating Disorder Completed NCT01098435 Phase 2 RDC-0313 (ALKS 33);Placebo

Search NIH Clinical Center for Bulimia Nervosa

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Fenfluramine
Fenfluramine Hydrochloride
Fluoxetine
Fluoxetine Hydrochloride
Maprotiline
Maprotiline Hydrochloride

Cochrane evidence based reviews: bulimia nervosa

Genetic Tests for Bulimia Nervosa

Genetic tests related to Bulimia Nervosa:

# Genetic test Affiliating Genes
1 Susceptibility to Bulimia Nervosa 29

Anatomical Context for Bulimia Nervosa

MalaCards organs/tissues related to Bulimia Nervosa:

40
Brain, Cortex, Bone, Prefrontal Cortex, Ovary, Kidney, Heart

Publications for Bulimia Nervosa

Articles related to Bulimia Nervosa:

(show top 50) (show all 5517)
# Title Authors PMID Year
1
Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. 57 61
18855537 2008
2
Linkage analysis of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits or covariates. 61 57
16152574 2005
3
Significant linkage on chromosome 10p in families with bulimia nervosa. 61 57
12476400 2003
4
Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. 61 57
11799475 2002
5
Linkage analysis of anorexia nervosa incorporating behavioral covariates. 61 57
11912184 2002
6
A preliminary population-based twin study of self-reported eating disorder. 57 61
11232922 2001
7
Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes. 57 61
10698815 2000
8
Twin studies of eating disorders: a review. 57 61
10590444 2000
9
A genetic analysis of the eating and attitudes associated with bulimia nervosa: dealing with the problem of ascertainment in twin studies. 61 57
10371753 1999
10
Heritability of binge-eating and broadly defined bulimia nervosa. 57 61
9861464 1998
11
A controlled family study of anorexia nervosa and bulimia nervosa: psychiatric disorders in first-degree relatives and effects of proband comorbidity. 57 61
9672050 1998
12
The genetic epidemiology of bulimia nervosa. 61 57
1842216 1991
13
Correlation of BDNF blood levels with interoceptive awareness and maturity fears in anorexia and bulimia nervosa patients. 61 54
20195875 2010
14
Enhanced ghrelin secretion in the cephalic phase of food ingestion in women with bulimia nervosa. 61 54
19631473 2010
15
The association of catechol-O-methyltransferase genotype with the phenotype of women with eating disorders. 61 54
19852950 2010
16
The possible influence of impulsivity and dietary restraint on associations between serotonin genes and binge eating. 61 54
19493540 2009
17
Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. 54 61
19741568 2009
18
Dietary restriction, cardiac autonomic regulation and stress reactivity in bulimic women. 54 61
19497332 2009
19
NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. 54 61
20066808 2009
20
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa. 61 54
19093738 2009
21
Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. 54 61
18728162 2008
22
Meal-induced compositional changes in blood and saliva in persons with bulimia nervosa. 61 54
18175732 2008
23
Hormonal alteration in obese adolescents with eating disorder: effects of multidisciplinary therapy. 61 54
18547953 2008
24
Clinical features and physiological response to a test meal in purging disorder and bulimia nervosa. 61 54
17768271 2007
25
Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: correlations between sympathovagal activity, clinical features, and leptin levels. 54 61
17598965 2007
26
The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. 61 54
16901635 2006
27
Association of catecholamine-O-methyltransferase and 5-HTTLPR genotype with eating disorder-related behavior and attitudes in females with eating disorders. 54 61
16969275 2006
28
Gastrointestinal disturbances in eating disorders: clinical and neurobiological aspects. 54 61
16962383 2006
29
Ghrelin concentrations and cardiac vagal tone are decreased after pharmacologic and cognitive-behavioral treatment in patients with bulimia nervosa. 61 54
16643914 2006
30
Investigation of the serotonin transporter regulatory region polymorphism in bulimia nervosa: relationships to harm avoidance, nutritional parameters, and psychiatric comorbidity. 61 54
16449418 2006
31
Association of eating disorders with catechol-o-methyltransferase gene functional polymorphism. 61 54
17028449 2006
32
Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa. 54 61
15940301 2005
33
Hormonal and metabolic responses to acute ghrelin administration in patients with bulimia nervosa. 54 61
15808922 2005
34
Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge-eating disorder: relationships to co-morbid depression, psychopathology and hormonal variables. 61 54
15997610 2005
35
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. 54 61
15841111 2005
36
Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. 54 61
15820714 2005
37
Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa. 61 54
15511598 2005
38
Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. 61 54
15598689 2005
39
Altered ghrelin and peptide YY responses to meals in bulimia nervosa. 61 54
15638873 2005
40
Clinical endocrinology and metabolism. Cholecystokinin. 54 61
15533776 2004
41
No changes in serum ghrelin levels in female patients with bulimia nervosa. 54 61
15610931 2004
42
The role of leptin in regulating neuroendocrine function in humans. 54 61
15333744 2004
43
Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. 54 61
15624269 2004
44
Adiponectin in anorexia nervosa and bulimia nervosa. 54 61
15070952 2004
45
Eating disorders, serotonin transporter polymorphisms and potential treatment response. 54 61
14987118 2004
46
Ghrelin and leptin responses to food ingestion in bulimia nervosa: implications for binge-eating and compensatory behaviours. 54 61
14672247 2003
47
Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. 61 54
12915293 2003
48
The role of leptin in the etiopathogenesis of anorexia nervosa and bulimia. 61 54
12880190 2003
49
Lower serum leptin levels in female students of the nutritional sciences with eating disorders. 61 54
12811471 2003
50
Leptin secretion is related to chronicity and severity of the illness in bulimia nervosa. 61 54
12461192 2002

Variations for Bulimia Nervosa

Expression for Bulimia Nervosa

Search GEO for disease gene expression data for Bulimia Nervosa.

Pathways for Bulimia Nervosa

Pathways related to Bulimia Nervosa according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 PYY OXT NPY MC4R LEP INS
2
Show member pathways
13.38 PYY OXT NPY MC4R LEP HTR2C
3 12.18 OXT NPY HTR1B GHRL DRD2 BDNF
5 12.04 SLC6A4 MAOA HTR3A HTR2A BDNF
6
Show member pathways
11.84 HTR2C HTR2A HTR1B DRD4 DRD2
7 11.79 SLC6A4 MAOA HTR3A HTR2C HTR2A HTR1B
8 11.63 HTR2C HTR2A DRD2
9 11.08 SLC6A4 MAOA HTR3A HTR2C HTR2A HTR1B
10
Show member pathways
11.07 SLC6A4 MAOA COMT
11
Show member pathways
10.79 SLC6A4 MAOA HTR1B DRD4 DRD2 COMT
12
Show member pathways
10.71 MAOA COMT
13 10.67 MAOA COMT
14 10.53 PYY NPY MC4R LEP INS HTR2C

GO Terms for Bulimia Nervosa

Cellular components related to Bulimia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.06 PYY OXT NPY LEP INS GHRL
2 integral component of plasma membrane GO:0005887 10.02 SLC6A4 HTR3A HTR2C HTR2A HTR1B DRD4
3 synapse GO:0045202 9.91 SLC6A4 NPY HTR3A HTR2C HTR2A DRD2
4 glutamatergic synapse GO:0098978 9.8 HTR3A HTR2A GHRL DRD4 DRD2
5 axon GO:0030424 9.8 HTR3A HTR2A GHRL DRD2 COMT CCK
6 integral component of postsynaptic membrane GO:0099055 9.62 SLC6A4 HTR3A HTR2A DRD2
7 dendrite GO:0030425 9.56 HTR2C HTR2A HTR1B DRD4 DRD2 COMT
8 serotonergic synapse GO:0099154 9.37 SLC6A4 HTR1B
9 G protein-coupled serotonin receptor complex GO:0098666 9.33 HTR2C HTR2A HTR1B
10 integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 HTR3A HTR2A HTR1B DRD2

Biological processes related to Bulimia Nervosa according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.1 OXT MC4R LEP INS HTR3A HTR2C
2 response to drug GO:0042493 10.02 SLC6A4 HTR2C HTR2A DRD2 COMT
3 chemical synaptic transmission GO:0007268 9.91 NPY HTR3A HTR2C HTR2A HTR1B DRD4
4 response to estradiol GO:0032355 9.89 SLC6A4 OXT LEP
5 positive regulation of cold-induced thermogenesis GO:0120162 9.89 OXT LEP GHRL
6 response to ethanol GO:0045471 9.89 LEP HTR3A HTR1B DRD2
7 female pregnancy GO:0007565 9.88 OXT LEP COMT
8 cellular calcium ion homeostasis GO:0006874 9.87 HTR2C HTR2A DRD4 DRD2
9 excitatory postsynaptic potential GO:0060079 9.85 HTR3A GHRL DRD2
10 glucose metabolic process GO:0006006 9.85 LEP INS GHRL
11 positive regulation of synapse assembly GO:0051965 9.83 OXT GHRL BDNF
12 social behavior GO:0035176 9.83 SLC6A4 OXT DRD4
13 regulation of synaptic vesicle exocytosis GO:2000300 9.82 HTR2A HTR1B DRD2
14 release of sequestered calcium ion into cytosol GO:0051209 9.8 HTR2C HTR2A DRD2
15 regulation of sensory perception of pain GO:0051930 9.77 OXT COMT CCK
16 response to amphetamine GO:0001975 9.76 OXT DRD4 DRD2
17 response to cocaine GO:0042220 9.76 OXT HTR3A HTR1B DRD2
18 regulation of dopamine secretion GO:0014059 9.75 HTR2A HTR1B DRD2
19 eating behavior GO:0042755 9.73 OXT LEP CCK
20 G protein-coupled receptor signaling pathway GO:0007186 9.73 PYY OXT NPY MC4R INS HTR2C
21 energy reserve metabolic process GO:0006112 9.72 MC4R LEP
22 negative regulation of protein secretion GO:0050709 9.72 INS DRD4 DRD2
23 positive regulation of renal sodium excretion GO:0035815 9.71 OXT DRD2
24 catecholamine metabolic process GO:0006584 9.71 MAOA COMT
25 G protein-coupled receptor internalization GO:0002031 9.71 HTR1B DRD2
26 dopamine metabolic process GO:0042417 9.71 DRD4 DRD2 COMT
27 grooming behavior GO:0007625 9.7 OXT DRD2
28 synaptic transmission, dopaminergic GO:0001963 9.7 DRD4 DRD2
29 neurotransmitter catabolic process GO:0042135 9.7 MAOA COMT
30 sleep GO:0030431 9.7 OXT HTR2A
31 behavior GO:0007610 9.7 HTR2C HTR2A HTR1B
32 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 DRD4 DRD2
33 negative regulation of appetite GO:0032099 9.69 LEP CCK
34 intestinal epithelial cell differentiation GO:0060575 9.69 PYY NPY
35 behavioral response to cocaine GO:0048148 9.69 HTR2A DRD4 DRD2
36 positive regulation of growth hormone secretion GO:0060124 9.68 GHRL DRD2
37 dopamine catabolic process GO:0042420 9.68 MAOA COMT
38 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.68 GHRL DRD2
39 behavioral response to ethanol GO:0048149 9.68 DRD4 DRD2
40 negative regulation of feeding behavior GO:2000252 9.67 MC4R INS
41 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 HTR2A HTR1B DRD2
42 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.67 HTR2C HTR2A HTR1B DRD4
43 serotonin receptor signaling pathway GO:0007210 9.66 HTR3A HTR2A
44 sperm ejaculation GO:0042713 9.65 SLC6A4 OXT
45 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.65 DRD4 DRD2
46 adult feeding behavior GO:0008343 9.65 NPY LEP GHRL
47 memory GO:0007613 9.65 SLC6A4 OXT HTR2A CCK BDNF
48 response to histamine GO:0034776 9.64 DRD4 DRD2
49 positive regulation of appetite GO:0032100 9.63 NPY GHRL
50 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.62 DRD4 DRD2

Molecular functions related to Bulimia Nervosa according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.95 NPY MC4R HTR2C HTR2A HTR1B DRD4
2 G protein-coupled receptor binding GO:0001664 9.7 PYY NPY GHRL
3 G protein-coupled serotonin receptor activity GO:0004993 9.62 HTR2C HTR2A HTR1B DRD4
4 neuropeptide hormone activity GO:0005184 9.56 PYY OXT NPY CCK
5 neurotransmitter receptor activity GO:0030594 9.55 HTR3A HTR2C HTR2A HTR1B DRD4
6 peptide hormone receptor binding GO:0051428 9.54 LEP CCK
7 dopamine binding GO:0035240 9.51 DRD4 DRD2
8 hormone activity GO:0005179 9.5 PYY OXT NPY LEP INS GHRL
9 dopamine neurotransmitter receptor activity GO:0004952 9.49 DRD4 DRD2
10 neuropeptide Y receptor binding GO:0031841 9.48 PYY NPY
11 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.46 DRD4 DRD2
12 Gq/11-coupled serotonin receptor activity GO:0001587 9.43 HTR2C HTR2A
13 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.37 HTR2C HTR2A
14 serotonin binding GO:0051378 9.02 SLC6A4 HTR3A HTR2C HTR2A HTR1B

Sources for Bulimia Nervosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....